InMed Pharmaceuticals (INM) Free Cash Flow (2019 - 2026)

InMed Pharmaceuticals' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$1.7 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 2.15% year-over-year to -$1.7 million in Q1 2026; TTM through Mar 2026 was -$7.5 million, a 6.27% decrease from a year earlier, with the FY2025 full-year figure at -$7.8 million, down 11.03% from the prior year.
• Free Cash Flow advanced to -$1.7 million in Q1 2026 per INM's latest filing, from -$2.4 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$823455.0 in Q2 2023 and bottomed at -$5.3 million in Q1 2022.
• The 5-year median for Free Cash Flow is -$1.8 million (2023), against an average of -$2.2 million.
• Across the five-year window, Free Cash Flow sank 106.42% in 2022 and soared 79.99% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$2.7 million in 2022, then jumped by 31.95% to -$1.8 million in 2023, then sank by 35.52% to -$2.5 million in 2024, then grew by 5.03% to -$2.4 million in 2025, then increased by 28.66% to -$1.7 million in 2026.
• Per Business Quant, the three latest INM Free Cash Flow figures stand at -$1.7 million (Q1 2026), -$2.4 million (Q4 2025), and -$1.6 million (Q3 2025).